Pemigatinib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

MPN (Myeloproliferative Neoplasms)

Conditions

MPN (Myeloproliferative Neoplasms)

Trial Timeline

Apr 25, 2017 → Oct 30, 2024

NCT ID

NCT03011372

About Pemigatinib

Pemigatinib is a phase 2 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT03011372. Target conditions include MPN (Myeloproliferative Neoplasms).

What happened to similar drugs?

0 of 1 similar drugs in MPN (Myeloproliferative Neoplasms) were approved

Approved (0) Terminated (0) Active (1)

🔄Ruxolitinib + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03906357	Pre-clinical	Completed	—	—	—
NCT07434843	Phase 2	Recruiting	Jun 1, 2026	Apr 1, 2029	SDH Gene Mutation
NCT06300528	Phase 2	Recruiting	Oct 3, 2025	Dec 1, 2030	Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT06906562	Phase 2	Recruiting	Aug 26, 2025	Dec 31, 2028	Advanced Pancreatic Carcinoma
NCT06653777	Phase 2	Recruiting	Mar 27, 2025	Jun 30, 2028	Solid Tumor, Miscellaneous
NCT05565794	Phase 2	Terminated	Nov 11, 2022	Mar 27, 2025	Intrahepatic Cholangiocarcinoma
NCT05267106	Phase 2	Terminated	May 20, 2022	Dec 17, 2024	Glioblastoma
NCT05253807	Phase 2	Completed	Apr 29, 2022	Aug 16, 2023	Non-Small Cell Lung Cancer (NSCLC)
NCT03914794	Phase 2	Completed	Oct 2, 2020	Sep 30, 2025	Bladder Cancer
NCT04294277	Phase 2	Terminated	Jul 13, 2020	Nov 15, 2022	Urothelial Cancer
NCT04003623	Phase 2	Terminated	Oct 31, 2019	Jun 12, 2020	Advanced or Metastatic Solid Tumors
NCT03822117	Phase 2	Terminated	Oct 17, 2019	Mar 29, 2022	Solid Tumor Malignancy
NCT03235570	Phase 1	Completed	Aug 1, 2017	Mar 4, 2020	Solid Tumors
NCT03011372	Phase 2	Completed	Apr 25, 2017	Oct 30, 2024	MPN (Myeloproliferative Neoplasms)
NCT02924376	Phase 2	Completed	Jan 16, 2017	Feb 1, 2022	Cholangiocarcinoma

Competing Products

6 competing products in MPN (Myeloproliferative Neoplasms)

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib	Incyte	Phase 2	32
Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib	Incyte	Phase 2	24
Ruxolitinib + Anagrelide + Placebo + Placebo	Incyte	Phase 2	24
itacitinib	Incyte	Phase 2	32
Ruxolitinib + Placebo	Incyte	Phase 3	37
Itacitinib + Ruxolitinib	Incyte	Phase 2	32